Damar Ugur, Gersner Roman, Johnstone Joshua T, Schachter Steven, Rotenberg Alexander
F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Biscayne Pharmaceuticals, Inc., Miami, FL, USA.
Med Hypotheses. 2017 Feb;99:57-62. doi: 10.1016/j.mehy.2016.12.006. Epub 2016 Dec 22.
Alzheimer's disease (AD) is the most frequent cause of dementia. Besides cognitive deterioration, patients with AD are prone to seizures - more than 20% of patients diagnosed with AD experience at least one unprovoked seizure and up to 7% have recurrent seizures. Although available antiepileptic drugs (AEDs) may suppress seizures in patients with AD, they may also worsen cognitive dysfunction and increase the risk of falls. On the basis of preclinical studies, we hypothesize that Huperzine A (HupA), a safe and potent acetylcholinesterase (AChE) inhibitor with potentially disease-modifying qualities in AD, may have a realistic role as an anticonvulsant in AD.
阿尔茨海默病（AD）是痴呆最常见的病因。除了认知功能衰退外，AD患者还容易发生癫痫发作——超过20%被诊断为AD的患者至少经历过一次无诱因癫痫发作，高达7%的患者有癫痫复发。虽然现有的抗癫痫药物（AEDs）可能会抑制AD患者的癫痫发作，但它们也可能会加重认知功能障碍并增加跌倒风险。基于临床前研究，我们推测石杉碱甲（HupA），一种安全有效的乙酰胆碱酯酶（AChE）抑制剂，在AD中可能具有潜在的疾病修饰作用，它可能在AD的抗惊厥治疗中发挥实际作用。
